Latanoprost And Timolol Accord (Timolol Maleate, Latanoprost)

Latanoprost increases uveoscleral outflow of aqueous humor by remodeling extracellular matrix, while timolol maleate reduces aqueous humor production through non‑selective beta‑adrenergic blockade of the ciliary epithelium. Together they achieve a greater reduction in eye pressure.

The dosing regimen for Latanoprost And Timolol Accord is determined by the prescribing clinician based on the patient’s condition, response, and tolerance. The prescriber will provide specific instructions on how many drops to instill and how often.

Safety data for the combination in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapy, the combination offers dual mechanisms—enhanced outflow and reduced production—often achieving greater pressure reduction with a single bottle, which can improve adherence versus using separate beta‑blocker and prostaglandin products.

Store the eye‑drop bottle at room temperature, preferably below 25 °C, in the original packaging. Protect it from direct light and moisture to maintain stability and potency.

The product is applied as sterile eye drops. The prescriber will instruct the patient to instill the recommended number of drops into the affected eye(s) at the specified interval, typically once daily, while avoiding contact with the tip of the bottle.

Serious risks include severe allergic reactions, marked bradycardia or hypotension, bronchospasm in patients with respiratory disease, and rare cases of corneal ulceration or vision loss. Patients should seek immediate medical attention if these symptoms occur.

Patients with known hypersensitivity to timolol, latanoprost, or any excipients, those with severe sinus bradycardia, second‑ or third‑degree heart block, uncontrolled asthma, or chronic obstructive pulmonary disease should avoid this medication unless directed by a physician.